×ðÁú¿­Ê±

EN
EN
  • ÓªÒµ×Éѯ

    Öйú£º

    Email: marketing@medicilon.com.cn

    ÓªÒµ×ÉѯרÏߣº400-780-8018

    £¨½öÏÞЧÀÍ×Éѯ £¬ÆäËûÊÂÒËÇ벦´ò´¨É³×ܲ¿µç»°£©

    ´¨É³×ܲ¿µç»°: +86 (21) 5859-1500

    ÍâÑó£º

    +1(781)535-1428(U.S.)

    0044 7790 816 954 (Europe)

    Email:marketing@medicilon.com

ÔÚÏßÁôÑÔ¡Á
µã»÷Çл»
News information
ÐÂÎÅ×ÊѶ

´Óϸ°û×÷Óýµ½Êý¾ÝÆÊÎö £¬ÊÖ°ÑÊÖ²ð½âCaco-2ʵÑéÈ«Á÷³Ì

2025-11-19
|
»á¼ûÁ¿£º

´Óϸ°û×÷Óýµ½Êý¾ÝÆÊÎö £¬×ðÁú¿­Ê±´øÄúÊÖ°ÑÊÖ²ð½âCaco-2ʵÑéÈ«Á÷³Ì ¡£

ÍÆ¼öÔĶÁ£ºCaco-2 ϸ°ûÉøÍ¸ÐÔÊÔÑé

Ïà¹ØÐÂÎÅ
Éè¼ÆºÏ³ÉºÍÆÀ¹ÀÓÃÓÚÖÎÁÆÇ°ÏßÏÙ°©µÄCBPäå½á¹¹ÓòÒÖÖÆ¼Á ¡£PKÆÀ¹À¡¢¸Î΢Á£ÌåÎȹÌÐԲⶨºÍCaco-2ÉøÍ¸ÐԲⶨͨ¹ý×ðÁú¿­Ê±¾ÙÐÐ
2023-07-05
Prostate cancer (PCa) is one of the most commonly diagnosed cancers and the leading cause of cancer mortalities in men. CREB (cyclic-AMP responsive element binding protein) binding protein (CBP) is a potential target for prostate cancer treatment. Researchers designed 1-(Indolizin-3-yl)ethan-1-ones as CBP bromodomain inhibitors for the treatment of prostate cancer. Pharmacokinetic properties evaluation were analyzed by Medicilon. Liver microsomal stability assay were performed at Medicilon. Caco-2 permeability assay was analyzed by Medicilon.
TRIM24ºÍBRPF1Êǰ©Ö¢µÄDZÔÚÖÎÁưеã ¡£Y08624ÊÇÒ»ÖÖÐÂÐÍTRIM24/BRPF1Ë«ÖØÒÖÖÆ¼Á £¬¾ßÓÐÓÅÒìµÄCaco-2ÉøÍ¸ÐÔ ¡£Caco-2 ÉøÍ¸ÐԲⶨͨ¹ý×ðÁú¿­Ê±¾ÙÐÐ
2023-07-06
TRIM24 (tripartite motif-containing protein 24) and BRPF1 (bromodomain and PHD finger containing protein 1) are epigenetics ¡°readers¡±and potential therapeutic targets for cancer and other diseases. Y08624 (Compound 20l) is a new TRIM24/BRPF1 dual inhibitor. Y08624 displays reasonable Caco-2 permeability. Caco-2 permeability assay was performed by Medicilon.
Caco-2 ϸ°ûÉøÍ¸ÐÔÊÔÑé
2023-08-08
Caco-2ϸ°ûÉøÍ¸ÐÔÊÔÑé¿ÉÒÔÌṩÓйػ¯ºÏÎïÔÚÄ£Ä⳦µÀÌõ¼þϵÄÎüÊÕÌØÕ÷µÄÖ÷ÒªÐÅÏ¢ ¡£Í¨¹ýÕÉÁ¿»¯ºÏÎïͨÏ꾡°û²ãµÄÄÜÁ¦ £¬ÆÀ¹ÀÆä±»ÎüÊÕµ½Ñ­»·ÏµÍ³ÖеÄDZÁ¦ £¬²¢Õ¹ÍûÆäÔÚÌåÄÚµÄÒ©´ú¶¯Á¦Ñ§ÐÐΪ ¡£
¡Á
ËÑË÷ÑéÖ¤
µã»÷Çл»
¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿